CD19-ARM
We are leveraging our expertise in T cell biology and protein engineering to develop a novel class of ARM bispecifics designed to address clinically validated drug targets. Our CD19 ARM is currently in IND-enabling studies.
CD19 is an important target for b-cell mediated diseases. We designed our CD19-ARM to drive prolonged drug free remissions as a fully off-the-shelf re-dosable therapeutic for autoimmune diseases.
In preclinical studies, CD19 ARM displayed full b-cell depletion in periphery and tissues with prolonged memory b-cell reset, but without CRS.
